The comparison between the resistant vs no‐resistant CML patients revealed higher MDA level (P = .02) and CAT and SOD activities in IM‐resistant patients (P = .04, P = .03). The gene discussed is SOD1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.